PACUPod is your trusted source for evidence-based insights tailored to advanced clinical pharmacists and physicians. Each episode dives into the latest primary literature, covering medication-focused studies across specialty pharmacy, and many more. We break down study designs, highlight key findings, and objectively discuss clinical implications—without the hype—so you stay informed and ready to apply new evidence in practice. Whether you’re preparing for board certification or striving for excellence in patient care, PACUPod helps you make sense of the data, one study at a time.
Britany: Welcome back to PACULit, your go-to source for the latest clinical literature updates. Today, Seth and I are diving into post hoc analyses from the VOYAGE 1 and 2 trials, focusing on guselkumab’s efficacy in moderate-to-severe plaque psoriasis. How are you doing today, Seth?
Seth: Doing great, Britany! Excited to unpack this data. Psoriasis is complex, and these long-term analyses help us understand treatment durability. Guselkumab, targeting IL-23, has been a game-changer.
Britany: Absolutely. Moderate-to-severe plaque psoriasis affects 2 to 3 percent globally. It’s more than a skin condition; it impairs quality of life and increases healthcare use. The IL-23/Th17 axis drives inflammation, so IL-23 biologics have revolutionized management.
Seth: Right, but questions remain—how durable is guselkumab’s response beyond initial trials? Does baseline severity or prior treatment affect long-term outcomes? These are key for tailoring therapy and counseling patients.
Britany: From specialty pharmacy and acute care perspectives, psoriasis patients often have flares or comorbidities needing multidisciplinary care. Knowing who maintains response long-term guides adherence strategies and risk-benefit discussions.
Seth: The study pools data from VOYAGE 1 and 2, Phase 3 RCTs with a 5-year open-label extension, assessing durability up to week 252—nearly five years.
Britany: The original VOYAGE trials were multicenter, double-blind, placebo- and active comparator-controlled. Patients got guselkumab 100 mg every 8 weeks, adalimumab 40 mg every 2 weeks, or placebo. Placebo crossed over at week 16; adalimumab patients had crossover or withdrawal per protocol.
Seth: Inclusion criteria: adults with moderate-to-severe plaque psoriasis—PASI ≥12, IGA ≥3, and ≥10% body surface area involvement—suitable for systemic therapy or phototherapy.
Britany: Patients with non-plaque psoriasis, active infections, or prior guselkumab exposure were excluded to ensure a homogenous population.
Seth: Primary outcome was IGA 0 or 1 (clear/almost clear skin). Secondary was PASI 90 (≥90% improvement). Post hoc analyses explored responses by baseline severity and prior treatment history.
Britany: Guselkumab dosing was 100 mg subcutaneously every 8 weeks after loading doses at weeks 0 and 4. Adalimumab was 40 mg every 2 weeks. This dosing difference impacts adherence and convenience.
Seth: The analysis was descriptive, focusing on subgroup response rates without new hypothesis testing—exploratory but clinically valuable.
Britany: Seth, what stood out in efficacy across baseline severity?
Seth: Guselkumab maintained high response rates through 5 years regardless of baseline severity. Patients with PASI below or above 20 had similar IGA 0/1 rates—about 81 to 86 percent. PASI 90 responses ranged 79 to 84 percent.
Britany: Even patients with severe baseline disease—IGA 4 or >20% body surface area—achieved comparable clearance. This shows robust efficacy across disease burdens.
Seth: Regarding prior treatment, patients with prior phototherapy or nonbiologic systemic therapy had high maintained responses. Biologic-experienced patients had slightly lower but still substantial responses—IGA 0/1 around 75 to 79 percent, PASI 90 between 71 and 76 percent.
Britany: That’s important since biologic-experienced patients are often more refractory. Sustained efficacy here supports guselkumab after prior biologic failure.
Seth: Clinically, this five-year durability is key when counseling patients on long-term expectations and reinforces adherence, especially with every-8-week dosing.
Britany: Less frequent dosing than adalimumab’s biweekly injections may improve satisfaction and persistence—something specialty pharmacists should emphasize.
Seth: Safety-wise, although this post hoc didn’t focus on it, original VOYAGE trials showed favorable long-term safety with low serious infections and no new signals over five years.
Britany: That’s reassuring, especially since psoriasis patients often have comorbidities like metabolic syndrome or cardiovascular disease. Safety data support guselkumab use, but individual risk assessment remains essential.
Seth: Guselkumab, as a monoclonal antibody, has minimal cytochrome P450 interactions, simplifying management compared to methotrexate or cyclosporine.
Britany: That’s a big advantage for patients on multiple meds. Still, monitoring for immunosuppression risks, especially latent infections or concomitant immunomodulators, is necessary.
Seth: The trials excluded active infections, reflecting this caution. In practice, screening for tuberculosis and hepatitis remains standard before starting guselkumab.
Britany: Methodologically, pooling VOYAGE 1 and 2 data increased sample size and power to explore subgroups. The 5-year open-label extension allowed assessment beyond original randomized periods.
Seth: Post hoc analyses have limits—selection bias, lack of randomization in subgroups—but provide valuable real-world insights. Understanding prior treatment effects helps personalize therapy.
Britany: Consistent response across baseline severity suggests clinicians can expect similar benefits regardless of initial disease burden, supporting early biologic initiation.
Seth: Early intervention may prevent progression and improve quality of life. Sustained PASI 90 responses indicate near-complete clearance—the ultimate goal.
Britany: Specialty pharmacists can use these findings to reinforce persistence and adherence, given psoriasis’s chronic nature.
Seth: Educating patients on the IL-23 blockade disrupting the Th17 pathway helps them understand guselkumab’s effectiveness and the importance of consistent dosing.
Britany: Any thoughts on how these findings might influence future research or practice?
Seth: These analyses pave the way for real-world studies in diverse populations, including those with comorbidities or varying adherence. Biomarkers predicting response could refine patient selection.
Britany: As new IL-23 inhibitors emerge, comparative effectiveness studies will guide optimal sequencing.
Seth: For now, VOYAGE post hoc data strongly support guselkumab’s durable efficacy and broad applicability.
Britany: To summarize, guselkumab shows sustained high skin clearance rates over five years across baseline severities and prior treatments. Its favorable dosing and safety make it a compelling option for moderate-to-severe plaque psoriasis.
Seth: Specialty pharmacists and clinicians should confidently recommend guselkumab, emphasizing adherence and monitoring to maximize outcomes.
Britany: Thanks for joining me today, Seth. Great deep dive into the VOYAGE analyses.
Seth: Thanks, Britany. Always a pleasure discussing cutting-edge literature with you.
Britany: And thank you to our listeners for tuning in to PACULit. Stay curious, stay informed, and we’ll catch you next time.
[End of transcript]